Human T cell responses to ESAT-6 and eight synthetic overlapping peptides were investigated in tuberculosis (TB) patients and control subjects from regions of high and low endemicity for TB. ESAT-6 was recognized by 65% of all tuberculin purified protein derivative-responsive TB patients, whereas only 2 of 29 bacille Calmette-Guérin-vaccinated Danish healthy donors recognized this molecule. In Ethiopia, a high frequency (58%) of healthy contacts of TB patients recognized ESAT-6. All of the peptides were recognized by some donors, indicating that the molecule holds multiple epitopes. Danish and Ethiopian patients differed in the fine specificity of their peptide responses. Recognition of the C-terminal region (aa 72-95) was predominant in Danish patients, whereas recognition of aa 42-75 was predominant in Ethiopia. The relationship of these differences to the distribution of HLA types in the two populations is discussed. This study demonstrates that ESAT-6 is frequently recognized during early infection and holds potential as a component of a future TB-specific diagnostic reagent.
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Tuberculosis (TB) is the leading killer of youth and adults in the developing world and will be responsible for the death of 30 million people within the next decade [1] . Coinfection with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis increases the risk of developing TB and enhances progression of HIV infection to AIDS [2] . In addition, multidrug-resistant TB is rapidly spreading, and new efficient measures to prevent and control the disease are urgently needed. For the development of both new vaccines and diagnostic reagents to replace tuberculin purified protein derivative (PPD), there is a need to identify and evaluate the human immune response against defined M. tuberculosis antigens.
In recent years, research has been focused on antigens released by live M. tuberculosis into the culture media, as these antigens are believed to be at least partially responsible for the efficacy of live vaccines. Pools of such extracellular antigens have been tested in several laboratories as subunit vaccines and demonstrated to induce substantial levels of protection in animal models [3] [4] [5] [6] [7] . The ESAT-6 antigen was purified from a strongly stimulatory, low-molecular-mass fraction of culture filtrate [5, 8, 9] and has attracted considerable interest in recent years, as it is recognized early during infection in several species, including mice [5, 10] , outbred guinea pigs [11, 12] , and cattle [13] . Recent data demonstrate that this antigen is expressed in M. tuberculosis but absent in Mycobacterium bovis bacille Calmette-Guérin (BCG) and most environmental mycobacterial species investigated [9, 14] . These findings have increased the interest in this molecule as both a potential vaccine candidate and a novel specific diagnostic reagent. The latter possibility was recently explored in bovine TB [15] . On the basis of the level of interferon (IFN)-g release from antigen-stimulated lymphocytes, ESAT-6 was found to discriminate between cattle infected with M. bovis and cattle sensitized with environmental mycobacteria.
The purpose of the present study was to evaluate human immune responses to ESAT-6, and our aim was to compare these data from regions of low and high endemicity for TB. Our study has allowed comparisons between ESAT-6 and PPD recognition in TB patients, household contacts, and BCG-vaccinated and nonvaccinated individuals from Denmark and Ethiopia.
Materials and Methods

Study Population
Ethiopia. Patients with TB were recruited by the physician from the local TB and Leprosy Control Program at Hossana District Hospital, Ethiopia. Hossana is the center of the South Shoa region, 200 miles south of Addis Ababa. Patients with sputumpositive pulmonary TB were asked to participate in the study and to give a blood sample before initiation of chemotherapy. Thirtyfour TB patients were included: 29 with severe TB and 5 with minimal TB according to the classification of the International Union against Lung Disease [16] . Household contacts were volunteers living for 16 months in the same house as the patient. The household contacts had a clinical and radiologic examination done at the hospital. Sputum samples, when available, were tested by microscopy and cultured at Armauer Hansen Research Institute (AHRI), Addis Ababa. Six household contacts were found to be positive for acid-fast bacilli at AHRI either by culture or by microscopy. Treatment was initiated, but these donors were not included in the present analysis. On the basis of radiographic findings, the household contacts were classified as either healthy or not healthy: 30 with normal radiographic appearance were classified as healthy. Nineteen contacts were found to have lesions on radiographs, and since an exact diagnosis could not be obtained and TB was not confirmed, these volunteers were excluded. Furthermore, 5 HIV-seropositive subjects (3 patients, 2 household contacts) and 9 donors with incomplete data were excluded. BCG scars were sought, but only 5 TB patients and 5 household contacts had a scar indicating previous BCG vaccination.
Denmark. Twenty-five patients (17 with minimal TB and 8 with severe TB) diagnosed and treated at the Department of Pulmonary Medicine, University Hospital of Copenhagen, were asked to participate in the study. Blood samples were drawn between 0 and 6 months after diagnosis. Twenty-nine BCG-vaccinated and 8 nonvaccinated persons were recruited as controls. Blood samples were drawn 2 months to 40 years after BCG vaccination. Donors with a history of person-to-person or laboratory exposure to M. tuberculosis were excluded. In Denmark, half of the TB patients are foreign-born immigrants from Africa, the Middle East, and the Far East [17] . To study any possible influence of HLA types on the peptide recognition pattern in Denmark and Ethiopia, we decided to exclude the non-Caucasian Danes from the peptide analysis.
Blood Sampling and Storage
Blood samples were drawn into tubes with either Li-heparin or Na-EDTA and processed within 24 h of sampling. In Ethiopia, blood samples were transported for 6-8 h by car to AHRI and rested overnight before separation. The study of TB patients is part of a longitudinal study, and peripheral blood mononuclear cells (PBMC) from the two study sites have been frozen and stored in liquid nitrogen for 1-6 months before in vitro stimulation.
Separation and Culture of PBMC
PBMC were separated from whole blood by density centrifugation as previously described [18] and frozen in liquid nitrogen [19] . PBMC were thawed and resuspended in RPMI 1640, supplemented with 40 mg/mL streptomycin, 40 U/mL penicillin, 0.04 mM glutamine (Life Technologies Laboratory, Paisley, UK), and 10% normal human AB Serum (local blood bank, Rigshospitalet, Copenhagen). Culture and IFN-g determinations were done independently in Denmark and Ethiopia by use of the same protocol. Briefly, triplicates of 1.5-PBMC, in a total volume of 0.2 5 2.5 ϫ 10 mL, were stimulated in vitro in round-bottom microtiter wells (Nunc, Roskilde, Denmark) with PPD, 2.5 mg/mL (RT23; Statens Serum Institut, Copenhagen), recombinant ESAT-6, 5 mg/mL [14] , or eight synthetic 20-to 24-mer peptides overlapping with 14 amino acids, 5 mg/mL [10] .
IFN-g Assay
After 5 days of antigen or peptide stimulation, supernatants were harvested, and IFN-g was determined by ELISA with commercially available reagents (PharMingen, San Diego). The mean (‫ע‬SD) IFN-g release into unstimulated wells was pg/mL 100 ‫ע‬ 30 in Ethiopian and pg/mL in Danish donors. The detection 30 ‫ע‬ 10 limit of the assay was 100 pg/mL, and individual antigen-or peptide-specific responses are shown as D values (IFN-g release in the antigen-stimulated well minus IFN-g release in the unstimulated well). Positive PPD, ESAT-6, and peptide responses were defined as D values 1300 pg/mL.
Statistics
Paired t test was used to compare responses to the antigens within each group. Mann-Whitney rank sum test was used for analyzing differences between groups. One-way analysis of variance on repeated measures was used to analyze the difference between the peptide responses.
Results
T cell responses to ESAT-6 in different groups of Danish donors.
IFN-g release from PBMC isolated from TB patients and BCG-vaccinated or nonvaccinated healthy persons from Denmark was monitored after in vitro stimulation with either PPD or ESAT-6 (figure 1). Twenty-five Danish TB patients responded strongly to PPD, with high median IFN-g production of 7510 pg/mL (25th-75th percentile, 5200-13,000). High levels of IFN-g, 6190 pg/mL (25th-75th percentile, 3110-9790), were also released by PBMC isolated from BCG-vaccinated subjects, whereas 5 of 8 non-BCG-vaccinated donors responded to PPD with a median IFN-g release of 2990 pg/mL (25th-75th percentile, 530-4430). Patients could be divided into ESAT-6-positive and ESAT-6-negative on the basis of IFN-g responses exceeding 300 pg/mL. Fourteen of the 25 Danish TB patients were ESAT-6-responsive, and in this group, high IFNg responses (2520 pg/mL; 25th-75th percentile, 740-4040) were found after stimulation, although not at the same level as induced by PPD in the same donors ( , paired t test). To P ! .001 address the question of whether the severity of the disease had an influence on the T cell response to ESAT-6, TB patients were characterized on the basis of radiologic findings and divided into patients with minimal and advanced TB. On the basis of these criteria, 71% (12/17) of the patients with minimal TB recognized ESAT-6, in contrast to only 25% (2/8) of patients with severe TB (results not shown). A number of Danish patients, who were tested several times during chemotherapy, remained ESAT-6-reactive, and likewise, a high proportion of the ESAT-6 nonresponders remained nonreactive to ESAT-6 over a 6-month observation period time (data not shown). In contrast to the patients, only 2 ESAT-6 responders were found in the group of 29 BCG-vaccinated donors; 1 showed a substantial IFN-g response (1210 pg/mL) and 1 was only marginally positive (320 pg/mL). Furthermore, no responders were detected within the group of healthy nonvaccinated Danish donors (figure 1). In summary, these results demonstrate that ESAT-6 is frequently recognized by TB patients and that T cell recognition of this antigen is almost exclusively restricted to persons infected with M. tuberculosis.
ESAT-6 recognition by TB patients and household contacts in Ethiopia. Investigation of ESAT-6 recognition was extended to include patients and household contacts from Ethiopia. T cell recognition of ESAT-6 was investigated not only in patients but also in household contacts with no radiologic or clinical symptoms of TB. Results from 34 TB patients and 30 healthy household contacts, all HIV-seronegative, were analyzed (figure 2). Compared with Danish TB patients, all of whom were PPDresponsive, only 21 (62%) of 34 Ethiopian TB patients responded to PPD, with a median IFN-g release in this group of 2200 pg/mL (25th-75th percentile, 840-3770; figure 2). A higher frequency (24/30, 80%) of the healthy household contacts responded to PPD, with higher levels of IFN-g in this group (5680 pg/mL; 25th-75th percentile, 3180-6760). The difference in IFN-g levels between patients and contacts was highly significant ( , Mann-Whitney rank sum test). The Ethio-P ! .002 pian donors were also divided into ESAT-6 responders and nonresponders. The ESAT-6 responders were all contained within the group of PPD-responsive donors. Of 34 patients, 11 responded to ESAT-6, with a median IFN-g response of 1320 pg/mL (25th-75th percentile, 510-2480), not significantly different from the PPD response ( , paired t test). In contrast P 1 .16 to the Danish patients, most of the Ethiopian patients (29/34, 85%) had advanced TB with clinical symptoms for many months before hospital contact. With only 5 patients categorized as having minimal TB, we found no difference in the ESAT-6 recognition between minimal and severe TB patients (data not shown). Among the healthy PPD-responsive household contacts, 14 responded to ESAT-6, with significantly higher levels of IFN-g (3780 pg/mL; 25th-75th percentile, 1280-6500) than seen in patients ( ). Together, these P ϭ .04 data demonstrate that Ethiopian patients and a notably high frequency of healthy contacts mount strong responses to ESAT-6.
ESAT-6 recognition by TB patients from different geographic regions. As described, different frequencies of responders to both complex mycobacterial antigens (PPD) and defined antigens (ESAT-6) were observed in Denmark and Ethiopia. Table  1 summarizes the frequency of PPD and ESAT-6 responders in Denmark and Ethiopia compared with data obtained in recent studies of antigen recognition by TB patients in Kuwait [20] , and in the United States (Lein D, et al., unpublished data). The patients recruited in Kuwait and Ethiopia were mostly patients with advanced disease, whereas in Denmark and the United States, patients with minimal disease were predominant. The frequency of PPD responders varied from 54% to 100%, and markedly lower frequencies of PPD responders were found in Ethiopia and Kuwait (54%-65%) than in Denmark and the United States (85%-100%). ESAT-6 responders were in all cases contained within the PPD-positive fraction of the patients studied, and 55%-84% of the PPD-positive subjects recognized ESAT-6 at the different study sites (table 1) . When the data obtained from all four study sites were taken together, T cell responses in a total of 121 patients were compared with those of the relevant control groups. The average frequency of ESAT-6 responders among PPD-positive patients was 65%, whereas Fine specificity of the T cell responses to ESAT-6 mapped by synthetic peptides. The fine specificity of the T cell responses to ESAT-6 was mapped by screening a panel of overlapping peptides covering the complete ESAT-6 sequence. The peptides were synthesized as 24 mers, with a 14-amino acid overlap, and were used to stimulate PBMC from Caucasian Danes and Ethiopians. PBMC were stimulated with the synthetic peptides, and IFN-g release was determined. Results from 23 Ethiopian patients or healthy contacts and 13 Danish patients who responded to either ESAT-6 or one of the peptides are shown in table 2. The pattern of T cell responses to the ESAT-6-derived peptides was highly heterogeneous, in the sense that all peptides were recognized by some donors and in most cases each donor recognized multiple peptides throughout the sequence. The magnitude of the IFN-g responses to the dominant peptides was in many cases comparable to or even higher than the level induced by the complete ESAT-6 antigen. Each donor recognized a particular set of peptides, and importantly, this characteristic pattern did not change when the patients were studied at consecutive time points during the course of chemotherapy ( figure 3) . A certain hierarchy existed, with certain regions being strong targets for the responses. Despite the heterogeneous recognition pattern, shown in table 2, it becomes clear that some regions of the molecule are both more frequently (table 2) and more strongly recognized than others (figure 4). In Ethiopia, the epitopes present in the central part of ESAT-6, aa 42-65 and 52-75, induced positive IFN-g responses in 57%-78% of the donors (table 2) . Moreover, the IFN-g response to aa 52-75 was significantly higher than the response to any of the other peptides except for the flanking peptide aa 42-65 (figure 4) ( , one-way analysis of variance on repeated measures). P ! .05 This epitope region was dominant in both healthy contacts and patients with severe disease. The fine specificity of the T cell response to ESAT-6 in Caucasian Danes differed from that in Ethiopian patients and household contacts. Only 23% of the Danish patients responded to either of the peptides in the central part of ESAT-6, strongly recognized by 57%-78% of the Ethiopian donors. In contrast, 46%-54% of the Danish patients showed the most frequent and pronounced recognition of peptides in the C-terminal region of ESAT-6 (aa 62-85 and 72-95) (table 2; figure 4 ). Within the group of Danish patients, the IFN-g response to aa 72-95 was significantly higher than the responses to any other peptide except the flanking peptide, aa 62-85 (
). There was a significant difference between Ethi-P ! .05 opian and Danish subjects in response to aa 42-75 ( ; P ! .05 figure 4), whereas differences between the two populations in response to the other peptides were not significant (Mann-Whitney rank sum test).
Discussion
The immunologic properties of ESAT-6 have been the subject of a number of studies in animal models, and it is known that this antigen is a prominent target broadly recognized early during disease in different species infected with M. tuberculosis or M. bovis [8, 10, 13] . The present study clearly demonstrates that ESAT-6 plays a similar role in human disease and is recognized by a high percentage (65%) of PPD-positive TB patients from various ethnic groups. ESAT-6 was originally identified by its potent induction of IFN-g from mouse memory Th1-type lymphocytes [8] [9] [10] , and the present study has shown that the human immune response to ESAT-6 has similar characteristics. In addition to these findings, a recent study of T cell responses to a large panel of purified mycobacterial antigens in PPDresponsive TB patients from Kuwait identified ESAT-6 as the most potent inducer of IFN-g, recognized by 84% of the subjects tested [20] .
It is known that ESAT-6 expression is restricted to the M. tuberculosis complex, whereas M. bovis BCG and the majority of environmental mycobacteria lack this antigen [9, 14] . The present study demonstrates that, in a country of low endemicity, such as Denmark, ESAT-6 recognition is highly specific for active TB and that healthy unexposed donors as well as BCGvaccinated PPD-positive donors do not recognize this antigen.
Attempts to improve specificity of the Mantoux test in humans involve dual skin testing with tuberculin PPD and M. avium sensitin [21, 22] as well as in vitro determination of IFNg responses to the same crude antigen preparations [23, 24] . The present study suggests that ESAT-6 holds potential for further improvement of specific TB diagnosis in humans. A parallel study has supported this idea by showing that IFN-g reactivity to ESAT-6 could discriminate between HIV-seronegative patients infected with M. tuberculosis and Mycobacterium avium complex. None of the M. avium complex-infected patients responded to ESAT-6, although they recognized PPD and M. avium sensitins (Lein D, unpublished data).
The finding in Ethiopia of pronounced responses to ESAT-6 by asymptomatic household contacts strongly indicates that these responsive donors represent actively infected persons at an early subclinical stage of infection. The present study does not present data for healthy Ethiopian persons with no known contacts with TB patients, because this group is very difficult to identify in a region of high endemicity. The results obtained in the Ethiopian household contacts are, therefore, not conclusive on their own, but are strongly suggestive of infection with M. tuberculosis. In support of this, we have found that highly exposed contacts (contacts of patients with severe TB) show much more pronounced T cell responses to a range of mycobacterial antigens, including ESAT-6, than do healthy contacts with low risk of infection (contacts of patients with minimal TB lesions). Taken together, our results suggest that recognition of ESAT-6 is indicative of infection with M. tu- berculosis, and a study of the clinical outcome in the group of ESAT-6-positive contacts is currently ongoing. Most Ethiopian TB patients presented with moderate and far-advanced disease, and a high frequency of these were nonresponders to PPD. Several studies have consistently shown that patients with active TB are characterized by depressed cellmediated immunity [25] [26] [27] [28] [29] [30] [31] . Boesen et al. [32] further demonstrated that this T cell depression was associated with advanced stages of TB, whereas patients with minimal TB were able to mount strong IFN-g responses. In full agreement with this study, a recent study [33] has shown that impaired antigenspecific IFN-g release by PBMC isolated from TB patients directly correlated with the severity of the disease as determined radiographically. Several explanations for the impaired T cell reactivity during advanced cases of TB have been suggested, such as sequestration of antigen-specific T cells at the site of infection [26, [34] [35] [36] , direct inhibition of T cell responses by cytokines (transforming growth factor-b) released by the infected macrophages [30] , or defects in functions of the antigenpresenting cells [37] . Also, external factors, such as malnutrition [38] , HIV coinfection [2] , and genetic factors [39, 40] , may trigger progression from minimal to advanced disease. A followup investigation of the household contacts will allow us to address the important question of whether suppressed antigenspecific T cell activity precedes the progression of disease or is a consequence of advanced disease.
Considering the small size of ESAT-6, our findings indicate that this molecule contains an unusually high number of T cell epitopes spanning the entire sequence of the antigen. Our study shows that all peptides from ESAT-6 are able to induce a T cell response in some persons, resulting in levels of IFN-g comparable to or even higher than that induced by the intact molecule. In addition, a recent study has shown recognition of peptides from the C-terminal end of ESAT-6 by IFN-gsecreting human CD8 T cells [41] . Together, these findings may explain why ESAT-6 is so frequently recognized by various animal species as well as genetically different human beings infected with M. tuberculosis.
It has not been within the scope of the present report to study the HLA restriction of the individual epitopes recognized, but we have presented preliminary data at the population level showing differences in T cell epitope recognition. The analysis of the major target peptides recognized in the populations revealed an interesting difference between Ethiopians and Danes. The epitope region most frequently recognized by Ethiopian patients and healthy contacts (aa 42-75) was different from the dominant region recognized by Caucasian Danes (aa 62-95), as shown in table 2 and figure 4. This observation suggests that the specificity of ESAT-6 epitope recognition in these regions may be due to differences in HLA molecules frequently expressed within the respective populations. Studies of HLA distribution in Africa show that two of the tribes included in our study (Oromo and Amhara) represent 75% of the Ethiopian population and share a high frequency of DR7 [42, 43] , a haplotype that is present in a low frequency among Caucasians [43, 44] . Running the sequence of ESAT-6 through the most recent version of the EpiMer epitope prediction algorithm, based on major histocompatibility complex binding [45] , led to the prediction of an epitope recognized by HLA-DR7 located in aa 43-52, the dominant epitope region in Ethiopia (de Groot A, personal communication). The identified motif is in full agreement with data from naturally processed self-epitopes eluted from HLA-DR7 [46] . HLA-DP has recently attracted interest as a restriction element for presentation of microbial antigens [47] . HLA-DPB1*0401 represents an HLA type that is much more frequent among Caucasian Danes (46%) than among African blacks (!12%) [44] . Interestingly, this HLA motif was predicted to bind two epitopes located in aa 8-18 and 73-81, of which the latter region corresponds to the C-terminal region of ESAT-6 (aa 72-95) most strongly recognized by the Danish TB patients.
Our data do not represent an exhaustive analysis of restriction elements, but the differences observed between ethnic groups underline the obvious problems associated with peptidebased vaccines or diagnostic reagents on a global scale.
The study provides data that demonstrate that ESAT-6 holds potential as a component of a new M. tuberculosis-specific diagnostic reagent. It holds numerous T cell epitopes, which ensures a strong recognition of the intact molecule in a high percentage of genetically different persons, and responses are specific for M. tuberculosis infection. The use of ESAT-6 for tracing contacts in a region of high endemicity such as Ethiopia may lead to the detection of a large number of healthy but latently M. tuberculosis-infected persons. It is known that 5% of exposed persons will progress to overt TB within a 2-year period [31] , and possibly a higher percentage of the ESAT-6-positive contacts will do so. The clinical outcome in ESAT-6-positive and -negative persons during a follow-up period will allow rational assessment of the need for early intervention to control infection before clinical disease develops. The critical question will thus be to evaluate whether prophylactic chemotherapy of the ESAT-6-positive healthy donors will reduce the number of cases of active TB.
